文献速递神经核医学心脏核医学

帕金森综合征患者单日SPECT与PET评估多巴胺转运体可用性、心脏神经支配及代谢模式的可行性

Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-11

本研究评估了在疑似α-突触核蛋白病患者中,单日内同时注射[123I]ioflupane和[123I]MIBG进行DaT-SPECT与心脏MIBG显像的可行性,并部分患者加做FDG-PET。结果显示双示踪剂方案图像质量良好,定量分析与单示踪剂无显著差异,可支持SyNeurGe生物学分类所需的影像生物标志物评估。

要点

  • 单日双示踪剂方案中,[123I]ioflupane在心脏无相关摄取,[123I]MIBG在脑内无相关摄取。
  • 10例双示踪剂方案患者中6例DaT-SPECT至少一侧半球结合显著降低(z值<-2),7例MIBG心脏/纵隔比异常。
  • 双示踪剂与单示踪剂扫描在图像质量和定量分析上无显著差异,FDG-PET也未见相关干扰。

核心结论

  • 单日DaT-SPECT、MIBG和FDG-PET方案有助于按SyNeurGe标准对帕金森综合征进行高效生物学表征所需的生物标志物评估。

研究设计与样本

  • 前瞻性可行性研究,先排除示踪剂交叉结合,再对10例临床疑似α-突触核蛋白病患者(9男1女,68.2±7.3岁)行单日双示踪剂显像,其中5例加做FDG-PET。

主要发现

  • 单示踪剂显像证实[123I]ioflupane在心脏无相关摄取,[123I]MIBG在脑内无相关摄取。
  • 10例双示踪剂方案患者中6例(帕金森病或多系统萎缩帕金森型)DaT-SPECT至少一侧半球结合显著降低(z值<-2),平均壳核z值-4.01±1.39。
  • 7例患者MIBG扫描心脏/纵隔比异常(平均H/M比1.12±0.08)。
  • DaT和MIBG图像均可视觉判读,无伪影或图像质量下降迹象,定量分析与单示踪剂扫描无显著差异。
  • 三重示踪剂方案患者的FDG-PET脑扫描在图像质量、表面投影生成和z值方面无相关干扰。

关键数值与推荐

  • DaT-SPECT结合显著降低定义为z值<-2。
  • MIBG扫描心脏/纵隔比异常未在原文给出具体阈值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Due to new advances in molecular and imaging biomarkers, a biological classification of Parkinson's disease (PD) called SyNeurGe (Hoglinger et al. Lancet Neurol 2024;23:191-204) has been proposed for research use recently. [123I]ioflupane dopamine transporter single-photon-emission-computed tomography (DaT-SPECT) and cardiac [123I]meta-iodobenzylguanidine (MIBG) scintigraphy are included in this biological classification scheme together with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) as central imaging biomarkers for the assessment of dopaminergic function, cardiac sympathetic denervation, and metabolic patterns in brain. In order to facilitate this prospectively high imaging demand and optimize diagnostic workup in PD we propose a single-day protocol. METHODS: First, we excluded relevant binding of MIBG in the brain as well as DaT in the heart by acquisition of brain scans in patients that received MIBG as well as by acquisition of chest scans in patients that received DaT. Then, we performed a single-day protocol including DaT-SPECT and cardiac MIBG scintigraphy in ten patients with clinically suspected α-synucleinopathies (9 male, 1 female; 68.2 ± 7.3 years). Both radiotracers were injected simultaneously and cardiac imaging was performed at 3.5 h after injection followed by brain imaging at 4 h after injection using standard protocols for MIBG-scintigraphy and DaT-SPECT. Additionally, five patients of the dual tracer protocol group received brain FDG-PET after DaT and MIBG imaging. RESULTS: Single tracer imaging confirmed no relevant uptake of [123I]ioflupane in the heart or [123I]MIBG in the brain. Six out of the ten dual tracer protocol patients (PD or multiple system atrophy with Parkinsonian phenotype (MSA-P)) showed a significantly reduced DaT-SPECT binding (z-score < -2) in at least one hemisphere (mean putaminal z-score -4.01 ± 1.39) while seven patients had a pathological heart-to-mediastinum ratio in the MIBG scan (mean H/M-ratio: 1.12 ± 0.08). Both DaT and MIBG scans could visually be interpreted without any signs of image artifacts or decrease in imaging quality and also quantitatively did not reveal significant differences to the single tracer scans. FDG-PET brain scans of the triple tracer protocol patients also showed no relevant interference in regard to image quality as well was generation of surface projections and z-scores. CONCLUSION: A single day protocol for DaT-SPECT, MIBG, and FDG-PET facilitates biomarker assessments needed for efficient biological characterization of Parkinsonian syndromes according to the SyNeurGe criteria.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Scheifele M, Gnörich J, Schröder E, et al. Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders. Eur J Nucl Med Mol Imaging. 2025. PMID: 40064709. doi:10.1007/s00259-025-07188-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。